A carregar...
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
B-RAF is mutated to a constitutively active form in 8% of human cancers including 50% of melanomas. In clinical trials, the RAF inhibitor, PLX4032 (vemurafenib), caused partial or complete responses in 48–81% of mutant B-RAF harboring melanoma patients. However, the average duration of response was...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3504716/ https://ncbi.nlm.nih.gov/pubmed/22858545 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cdd.2012.94 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|